Armatus Reports Promising Breakthrough Data on TVR110, a Vectorized MicroRNA Therapy for Charcot-Marie-Tooth Disease Type 1A
Armatus Bio, a late-preclinical biotechnology company focused on developing next-generation vectorized RNA interference (RNAi) therapies for neuromuscular disorders, has announced the publication of important foundational data supporting its lead candidate, TVR110. The findings, published in Molecular Therapy Nucleic Acids, provide new insights into the safety, biodistribution, and therapeutic potential of this investigational treatment for Charcot-Marie-Tooth disease type 1A (CMT1A), a progressive inherited neuropathy with no currently approved disease-modifying therapies.
The study represents a significant milestone for Armatus Bio, as it validates a novel approach to gene silencing using a vectorized microRNA delivered via an adeno-associated virus (AAV) platform. Specifically, TVR110 leverages an AAV9 vector to deliver a precision-engineered microRNA designed to reduce the overexpression of the PMP22 gene, the underlying genetic driver of CMT1A. The research was conducted in collaboration with leading scientific institutions, including the Nationwide Children’s Hospital Center for Gene Therapy and the Cyprus Institute of Neurology and Genetics, underscoring the collaborative effort behind this innovative therapeutic strategy.
CMT1A is caused by a duplication of the PMP22 gene, which leads to excessive production of the PMP22 protein. This overproduction disrupts the structure and function of myelin—the protective sheath surrounding peripheral nerves—resulting in progressive nerve damage. Patients with CMT1A experience symptoms such as muscle weakness, sensory loss, and impaired motor function, which worsen over time. Despite its prevalence as one of the most common inherited neurological disorders, there are currently no approved therapies that directly address the root cause of the disease.
TVR110 is designed to correct this genetic imbalance by selectively reducing PMP22 expression to near-normal physiological levels. By restoring the balance of this critical protein, the therapy aims to improve myelin integrity and ultimately enhance nerve function. The newly published data provide compelling evidence that this approach may be both effective and durable.
One of the most significant findings from the study is that a single intrathecal (IT) injection of the AAV9-delivered microRNA was able to achieve broad biodistribution across the peripheral nervous system. Intrathecal administration, which involves delivery into the cerebrospinal fluid via the lumbar region, enabled the therapy to reach distal Schwann cells—specialized cells responsible for producing myelin in peripheral nerves. These cells are a critical target for treating CMT1A, as they are directly affected by PMP22 overexpression.
In preclinical mouse models of CMT1A, a single administration of TVR110 resulted in a meaningful reduction in PMP22 mRNA and protein levels. This reduction was associated with improvements in disease-related outcomes, including enhanced nerve histology, better myelin structure, and improved functional behavior. These findings suggest that the therapy not only addresses the molecular cause of the disease but also translates into measurable physiological benefits.
To further evaluate the translational potential of TVR110, the researchers conducted comprehensive studies in large animal models, including non-human primates (NHPs). These studies were designed to assess biodistribution, target engagement, and safety at doses relevant for potential human use. The results demonstrated that lumbar intrathecal delivery of AAV9 enabled widespread distribution of the therapeutic vector throughout peripheral nerves, including key structures such as the sciatic and femoral nerves. Importantly, the therapy was able to reach distal nerve regions that are often difficult to access with conventional delivery methods.
The ability to achieve such broad and durable distribution with a single administration represents a major advancement in the field of gene therapy for neuromuscular disorders. Traditional non-viral approaches often require repeated dosing to maintain therapeutic effects, which can be burdensome for patients and may increase the risk of adverse events. In contrast, the AAV9 platform used in TVR110 takes advantage of the virus’s natural tropism for Schwann cells, potentially enabling long-lasting therapeutic effects from a single treatment.
Scott Harper, Ph.D., Principal Investigator at the Nationwide Children’s Hospital Center for Gene Therapy and Chief Scientific Advisor to Armatus Bio, highlighted the significance of these findings. He noted that the study provides strong evidence that AAV9 can effectively reach distal Schwann cells in large animals following a single lumbar injection. He also emphasized the precision of the engineered microRNA, which enables controlled silencing of PMP22 without affecting other genes.
A key aspect of the study was the evaluation of target engagement and dose optimization. At the selected target doses—6×10¹³ vector genomes (vg) and 1.2×10¹⁴ vg—TVR110 achieved an average reduction of approximately 38% in PMP22 mRNA and protein levels across the sciatic nerve. This level of knockdown is predicted to bring PMP22 expression in patients close to normal physiological levels (approximately 93%), while avoiding the risks associated with excessive gene silencing. Maintaining this balance is critical, as both overexpression and underexpression of PMP22 can lead to neurological complications.
The study also provided robust evidence of safety and specificity. No significant toxicities were observed in the animal models, including the absence of inflammation in the dorsal root ganglia (DRG), a potential concern in gene therapy approaches targeting the nervous system. Additionally, extensive RNA sequencing analysis covering approximately 16,000 transcripts confirmed that PMP22 was the only gene consistently downregulated to clinically relevant levels. This high degree of specificity is further supported by the finding that the engineered microRNA exhibited a 25-fold higher binding affinity for PMP22 compared to any other genomic target.
These results collectively demonstrate that TVR110 has the potential to deliver precise, titratable gene silencing with a favorable safety profile. The combination of efficacy, durability, and specificity positions the therapy as a highly differentiated candidate within the emerging landscape of genetic treatments for neuromuscular diseases.
Rachel Salzman, DVM, Chief Executive Officer of Armatus Bio, подчеркнул the broader implications of the study. She stated that the data address one of the primary challenges in developing therapies for CMT1A—namely, achieving widespread and sustained delivery of a therapeutic agent across the peripheral nervous system. By demonstrating that this can be accomplished with a single administration, the study provides a strong foundation for advancing TVR110 into human clinical trials.
Dr. Salzman also highlighted the importance of achieving controlled gene silencing without the toxicities observed in earlier-generation approaches. This balance is critical for ensuring both safety and long-term efficacy, particularly in chronic conditions that require sustained therapeutic effects. She described TVR110 as a highly differentiated product with a clear and de-risked path toward clinical development.
Beyond its implications for CMT1A, the study also supports the broader application of vectorized RNAi technologies for other neuromuscular disorders. Many of these conditions are driven by well-defined genetic abnormalities, making them suitable targets for gene-silencing approaches. The success of TVR110 in preclinical models suggests that similar strategies could be applied to address a range of diseases with significant unmet medical needs.
In conclusion, the publication of these foundational data marks a significant milestone for Armatus Bio and the field of gene therapy. By demonstrating the feasibility of delivering a precise, durable, and safe gene-silencing therapy to peripheral nerves, the study provides strong support for the continued development of TVR110. As the company moves toward clinical trials, these findings offer hope for patients with CMT1A and highlight the potential of innovative RNAi-based therapies to transform the treatment landscape for neuromuscular disorders.
About CMT1A
Charcot-Marie-Tooth disease type 1A is a peripheral nerve demyelination and axon degeneration disease caused by a duplication of the PMP22 gene, which leads to the production of an abnormal amount of peripheral myelin protein 22 (PMP22). The disease affects over 150,000 people in the U.S. and EU. It typically presents in the teenage or young adult years, and leads to progressive muscle weakness and sensory loss in the extremities that often results in severe disability, pain, and loss of independence. There are currently no approved disease-modifying therapies or curative interventions for CMT1A.
About Armed
Armatus Bio is a late-preclinical stage, privately held biotech innovator developing advanced medicines that leverage vectorized RNAi (RNA interference). Armatus’ uniquely specific, engineered microRNAs are noncoding RNAs responsible for regulating gene expression by mirroring innate cellular biogenesis processes without altering the underlying genetic make-up.
The company’s two lead assets are designed to target neuromuscular disorders: TVR110 for Charcot-Marie-Tooth disease type 1A (CMT1A), and ARM-201 for Facioscapulohumeral Muscular Dystrophy (FSHD), which together affect more than 225,000 people in the U.S. and European Union. In preclinical studies, these investigational drugs demonstrated robust signals of target engagement and biomarker improvement, and both are advancing toward the clinic.
Source Link:https://www.businesswire.com/
